Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS-207 in MSI-H Advanced Solid Tumors
NCT07593144Phase 1Not yet recruiting
- Sponsor
- Foresight Therapeutics
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FS-207 in solid tumor (2 arms), sponsored by Foresight Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days and Treatment-emergent Adverse Events and Serious Adverse Events at 3 years. Planned start May 2026; status: not yet recruiting.
02
Drugs
FS-207
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07593144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593144.